AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A dosage form comprising:

a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle comprising dalbavancin factor B_0 and at least one additional dalbavancin factor selected from the group consisting of dalbavancin factors A_0, A_1, B_1, C_0, and C_1;

wherein the content of factor B_0 is not less than about 75 mole percent of all dalbavancin components present and

wherein a content of MAG does not exceed about 4 mole percent of all dalbavancin components present.

2. (Original) The dosage form of claim 1, further comprising a stabilizing substance.

3. (Original) The dosage form of claim 2, wherein the stabilizing substance is mannitol.

4. (Original) The dosage form of claim 2, wherein the stabilizing substance is a mixture of mannitol and lactose.

5-14. (Canceled)

15. (Original) A pharmaceutical composition comprising:

dalbavancin factor B_0 and at least one additional dalbavancin factor selected from the group consisting of dalbavancin factors A_0, A_1, B_1, C_0, and C_1; and

wherein the content of factor B_0 is not less than about 75 mole percent of all dalbavancin components present, and

wherein a content of MAG does not exceed 4 mole percent of all dalbavancin components present.

16. (Original) The pharmaceutical composition of claim 15, further comprising a stabilizing substance.

17. (Original) The pharmaceutical composition of claim 16, wherein the stabilizing substance is mannitol.

18. (Original) The pharmaceutical composition of claim 16, wherein the stabilizing substance is a mixture of mannitol and lactose.

19-28. (Canceled)

29. (Original) A dosage form comprising:

a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle comprising dalbavancin factor B_0 and MAG; and

wherein the content of factor B_0 is not less than about 75 mole percent of all dalbavancin components present and

wherein the content of MAG does not exceed about 4 mole percent of all dalbavancin components present.

30. (Original) The dosage form of claim 29, further comprising a stabilizing substance.

31. (Original) The dosage form of claim 30, wherein the stabilizing substance is mannitol.

32. (Original) The dosage form of claim 30, wherein the stabilizing substance is a mixture of mannitol and lactose.

33-42. (Canceled)

43. (Original) A pharmaceutical composition comprising:

dalbavancin factor B_0 and MAG; and

wherein the content of factor B_0 is not less than about 75 mole percent of all dalbavancin components present, and

wherein the content of MAG does not exceed 4 mole percent of all dalbavancin components present.

44. (Original) The pharmaceutical composition of claim 43, further comprising a stabilizing substance.

45. (Original) The pharmaceutical composition of claim 44, wherein the stabilizing substance is mannitol.

46. (Original) The pharmaceutical composition of claim 44, wherein the stabilizing substance is a mixture of mannitol and lactose.

47-56. (Canceled)